You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Do antidrug antibodies (ADA) affect the pharmacokinetics, efficacy, or safety of ZEPBOUND® (tirzepatide)?
No clinically significant effect of ADA on the PK or effectiveness of tirzepatide has been identified. There were more hypersensitivity or injection site reactions in tirzepatide-treated patients who developed ADA compared with those who did not.
See important safety information, including boxed warning, in the attached prescribing information.
Antidrug Antibodies in Phase 3 Studies for Obesity or Overweight
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay used. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies.1
The incidence of ADA to tirzepatide was evaluated in adult patients with overweight or obesity, or with obstructive sleep apnea (OSA) and obesity, in clinical studies lasting 52 weeks or longer. Anti-tirzepatide antibodies were detected in 64.5% (1591/2467) of tirzepatide-treated patients in weight reduction clinical studies SURMOUNT-1 and SURMOUNT-2.1
Antibody Category |
SURMOUNT-1 and -2 |
|---|---|
Anti-tirzepatide antibodies |
64.5% (1,591/2,467) |
Antibodies cross-reactive to native GIP |
40% |
Antibodies cross-reactive to native GLP-1 |
16.5% |
Neutralizing antibodies against tirzepatide activity on the GIP receptor |
2.8% |
Neutralizing antibodies against tirzepatide activity on the GLP-1 receptor |
2.7% |
Neutralizing antibodies against native GIP |
0.8% |
Neutralizing antibodies against native GLP-1 |
0.1% |
Abbreviations: GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide.
No clinically significant effect of anti-tirzepatide antibodies on the pharmacokinetics or effectiveness of tirzepatide has been identified.1
More tirzepatide-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies. See Table 2 for incidence from a pool of SURMOUNT-1 and -2 studies.1
Adverse Reaction |
Patients With Anti-Tirzepatide Antibodies |
Patients Without Anti-Tirzepatide Antibodies |
|---|---|---|
Hypersensitivity reactions |
6.2% |
3% |
Injection site reactions |
11.3% |
1% |
Enclosed Prescribing Information
ZEPBOUND® (tirzepatide) Injection, for subcutaneous use, Lilly
Reference
- Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: September 15, 2026